Additional development and milestone payments receivable.

No definition available.

Name:	teva_AdditionalDevelopmentAndMilestonePaymentsReceivable
Namespace Prefix:	teva_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Aggregate Upfront And Milestone Payments.

+ References

No definition available.

+ Details

Name:	teva_AggregateUpfrontAndMilestonePayments
Namespace Prefix:	teva_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Collaboration Partner Funding Reimbursements

+ References

No definition available.

+ Details

Name:	teva_CollaborationPartnerFundingReimbursements
Namespace Prefix:	teva_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Collaborative Agreement Milestone Payments

+ References

No definition available.

+ Details

Name:	teva_CollaborativeAgreementMilestonePayments
Namespace Prefix:	teva_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Collaborative Agreement Milestone Payments, Period

+ References

No definition available.

+ Details

Name:	teva_CollaborativeAgreementMilestonePaymentsPeriod
Namespace Prefix:	teva_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Development and launch milestone payment receivable.

+ References

No definition available.

+ Details

Name:	teva_DevelopmentAndLaunchMilestonePaymentReceivable
Namespace Prefix:	teva_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Increase in development funding commitment.

+ References

No definition available.

+ Details

Name:	teva_IncreaseInDevelopmentFundingCommitment
Namespace Prefix:	teva_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

License agreement potential aggregate milestone payments amount.

+ References

No definition available.

+ Details

Name:	teva_LicenseAgreementPotentialAggregateMilestonePaymentsAmount
Namespace Prefix:	teva_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Milestone payment.

+ References

No definition available.

+ Details

Name:	teva_MilestonePayment
Namespace Prefix:	teva_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Milestone Payment, Aggregate Cap Per Company

+ References

No definition available.

+ Details

Name:	teva_MilestonePaymentAggregateCapPerCompany
Namespace Prefix:	teva_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Milestone Payment, Payment One

+ References

No definition available.

+ Details

Name:	teva_MilestonePaymentPaymentOne
Namespace Prefix:	teva_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Milestone Payment, Payment Two

+ References

No definition available.

+ Details

Name:	teva_MilestonePaymentPaymentTwo
Namespace Prefix:	teva_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Milestone payment percentage cap.

+ References

No definition available.

+ Details

Name:	teva_MilestonePaymentPercentageCap
Namespace Prefix:	teva_
Data Type:	xbrli:pureItemType
Balance Type:	na
Period Type:	instant

- Definition

Milestone payment receivable.

+ References

No definition available.

+ Details

Name:	teva_MilestonePaymentReceivable
Namespace Prefix:	teva_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Milestone payment to be paid.

+ References

No definition available.

+ Details

Name:	teva_MilestonePaymentToBePaid
Namespace Prefix:	teva_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Number of Additional Candidates

+ References

No definition available.

+ Details

Name:	teva_NumberOfAdditionalCandidates
Namespace Prefix:	teva_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of Candidates

+ References

No definition available.

+ Details

Name:	teva_NumberOfCandidates
Namespace Prefix:	teva_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of Candidates With Line Extensions

+ References

No definition available.

+ Details

Name:	teva_NumberOfCandidatesWithLineExtensions
Namespace Prefix:	teva_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Phase 2b funding option amount.

+ References

No definition available.

+ Details

Name:	teva_Phase2bfundingoptionamount
Namespace Prefix:	teva_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Phase 3 funding option amount.

+ References

No definition available.

+ Details

Name:	teva_Phase3fundingoptionamount
Namespace Prefix:	teva_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of liability recognized from contingent consideration in asset acquisition.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 50
-Name Accounting Standards Codification
-Section 15
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480123/805-50-15-3

+ Details

Name:	us-gaap_AssetAcquisitionContingentConsiderationLiability
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482913/230-10-50-3

+ Details

Name:	us-gaap_NoncashOrPartNoncashAcquisitionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.9-06)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3

+ Details

Name:	us-gaap_OtherCommitment
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 50
-Name Accounting Standards Codification
-Section 25
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480060/805-50-25-1

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 50
-Name Accounting Standards Codification
-Section 30
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480027/805-50-30-1

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 50
-Name Accounting Standards Codification
-Section 30
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480027/805-50-30-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 13
-Subparagraph (c)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-13

+ Details

Name:	us-gaap_PaymentsToAcquireProductiveAssets
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 730
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483041/730-20-50-1

+ Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_AssetAcquisitionAxis=teva_BioXcelTherapeuticsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=teva_SamsungBioepisMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=srt_ScenarioForecastMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementOfIncomeLocationBalanceAxis=us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=teva_SanofiMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=teva_PolpharmaBiologicsInternationalAGMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=teva_BlackstoneLifeSciencesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=teva_MabxienceMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=teva_AbingworthMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=teva_BiolojicDesignLtdMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=teva_RoyaltyPharmaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementOfIncomeLocationBalanceAxis=us-gaap_OtherOperatingIncomeExpenseNet
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=teva_ModagMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=teva_AlvotechMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=teva_MedincellMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Certain transactions - Other Significant Agreements Narrative (Detail) $ in Millions							1 Months Ended								3 Months Ended											9 Months Ended		12 Months Ended			81 Months Ended
	Nov. 03, 2026 USD ($) candidate	Oct. 09, 2026 USD ($)	Jun. 04, 2026 candidate	Mar. 03, 2026 USD ($)	Jan. 11, 2026 USD ($)	Nov. 09, 2023 USD ($)	Sep. 30, 2026 USD ($) candidate	Aug. 31, 2026 USD ($)	Jan. 31, 2026 USD ($)	Dec. 31, 2025 USD ($)	Jul. 31, 2023 candidate	Oct. 31, 2021 USD ($)	Aug. 31, 2020 candidate	Nov. 30, 2013 USD ($)	Dec. 31, 2026 USD ($)	Sep. 30, 2026 USD ($)	Jun. 30, 2026 USD ($)	Mar. 31, 2026 USD ($)	Dec. 31, 2025 USD ($)	Sep. 30, 2025 USD ($)	Jun. 30, 2025 USD ($)	Mar. 31, 2025 USD ($)	Dec. 31, 2024 USD ($)	Sep. 30, 2022 USD ($)	Dec. 31, 2021 USD ($)	Sep. 30, 2026 USD ($)	Sep. 30, 2025 USD ($)	Dec. 31, 2025 USD ($)	Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)	Sep. 30, 2026 USD ($)	Mar. 28, 2024 USD ($)	Oct. 03, 2023 USD ($)
Noncash or Part Noncash Acquisitions [Line Items]
Payments to acquire assets																$ 120				$ 136						$ 393	$ 359
Other commitment																																$ 150
BioXcel Therapeutics
Noncash or Part Noncash Acquisitions [Line Items]
Payments to acquire assets								$ 58
Contingent liability								$ 68
Samsung Bioepis \| Collaborative arrangement
Noncash or Part Noncash Acquisitions [Line Items]
Number of candidates \| candidate	2						2
Number of additional candidates \| candidate							4
Aggregate cap per company							$ 122
Samsung Bioepis \| Collaborative arrangement \| Subsequent event \| Forecast
Noncash or Part Noncash Acquisitions [Line Items]
Collaborative agreement milestone payments	$ 370
Samsung Bioepis \| Maximum \| Collaborative arrangement
Noncash or Part Noncash Acquisitions [Line Items]
Number of candidates \| candidate							6
Samsung Bioepis \| Income Statement Location [Axis]: us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost \| Collaborative arrangement
Noncash or Part Noncash Acquisitions [Line Items]
Milestone payment																8
Samsung Bioepis \| Income Statement Location [Axis]: us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost \| Collaborative arrangement \| Subsequent event
Noncash or Part Noncash Acquisitions [Line Items]
Milestone payment	$ 50
Sanofi
Noncash or Part Noncash Acquisitions [Line Items]
Milestone payment one																			$ 250
Milestone payment two																			$ 250
Sanofi \| Collaborative arrangement
Noncash or Part Noncash Acquisitions [Line Items]
Milestone payment receivable																																	$ 500
Development and launch milestone payment receivable																																	$ 500
Polpharma
Noncash or Part Noncash Acquisitions [Line Items]
License agreement potential aggregate milestone payments amount										$ 92
Polpharma \| Income Statement Location [Axis]: us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
Noncash or Part Noncash Acquisitions [Line Items]
Milestone payment																15	$ 15
Blackstone Life Sciences
Noncash or Part Noncash Acquisitions [Line Items]
Collaborative agreement milestone payments				$ 400
Collaborative agreement milestone payments, period				4 years
Blackstone Life Sciences \| Income Statement Location [Axis]: us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
Noncash or Part Noncash Acquisitions [Line Items]
Reimbursement of research and development expenses incurred																30	30	$ 30
mAbxience
Noncash or Part Noncash Acquisitions [Line Items]
Collaborative agreement milestone payments																286
mAbxience \| Income Statement Location [Axis]: us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
Noncash or Part Noncash Acquisitions [Line Items]
Milestone payment																5												$ 29
Aggregate upfront and milestone payments																							$ 15						$ 20
Abingworth
Noncash or Part Noncash Acquisitions [Line Items]
Increase in development funding commitment									$ 50
Collaboration partner funding reimbursements							$ 200									200										200					$ 200
Abingworth \| Income Statement Location [Axis]: us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
Noncash or Part Noncash Acquisitions [Line Items]
Reimbursement of research and development expenses incurred																	30	30										98	42
Biolojic Design \| Collaborative arrangement
Noncash or Part Noncash Acquisitions [Line Items]
Additional development and milestone payments receivable																					$ 500
Biolojic Design \| Income Statement Location [Axis]: us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
Noncash or Part Noncash Acquisitions [Line Items]
Milestone payment																		5										$ 5	10
Royalty Pharma
Noncash or Part Noncash Acquisitions [Line Items]
Collaborative agreement milestone payments					$ 500	$ 100
Reimbursement of research and development expenses incurred																$ 8	$ 16
Phase 2b funding option amount					75
Phase 3 funding option amount					$ 425
Royalty Pharma \| Collaborative arrangement \| Subsequent event
Noncash or Part Noncash Acquisitions [Line Items]
Collaborative agreement milestone payments, period															4 years
Royalty Pharma \| Minimum
Noncash or Part Noncash Acquisitions [Line Items]
Milestone payment percentage cap					1
Royalty Pharma \| Maximum
Noncash or Part Noncash Acquisitions [Line Items]
Milestone payment percentage cap					1.30
Royalty Pharma \| Income Statement Location [Axis]: us-gaap:OtherOperatingIncomeExpenseNet \| Collaborative arrangement \| Subsequent event
Noncash or Part Noncash Acquisitions [Line Items]
Milestone payment															$ 50
Royalty Pharma \| Income Statement Location [Axis]: us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost \| Collaborative arrangement
Noncash or Part Noncash Acquisitions [Line Items]
Reimbursement of research and development expenses incurred																													$ 100	$ 100
MODAG
Noncash or Part Noncash Acquisitions [Line Items]
License agreement potential aggregate milestone payments amount												$ 20
MODAG \| Income Statement Location [Axis]: us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
Noncash or Part Noncash Acquisitions [Line Items]
Milestone payment																									$ 10
Milestone payment to be paid																					$ 10
Alvotech
Noncash or Part Noncash Acquisitions [Line Items]
Number of candidates \| candidate			3										5
Milestone payment																		$ 20													$ 154
Number of additional candidates \| candidate											2
Candidates with line extensions \| candidate											2
Collaborative agreement milestone payments																										$ 320
MedinCell
Noncash or Part Noncash Acquisitions [Line Items]
Milestone payment																								$ 3
Collaborative agreement milestone payments														$ 105
MedinCell \| Subsequent event
Noncash or Part Noncash Acquisitions [Line Items]
Collaborative agreement milestone payments		$ 108
MedinCell \| Income Statement Location [Axis]: us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
Noncash or Part Noncash Acquisitions [Line Items]
Milestone payment																						$ 5
MedinCell \| Income Statement Location [Axis]: us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost \| Subsequent event
Noncash or Part Noncash Acquisitions [Line Items]
Milestone payment		$ 4